TB-500 (Thymosin Beta-4)

Mechanism of Action

TB-500 is a synthetic peptide representing the active region of thymosin beta-4, specifically the N-terminal acetylated 17-23 amino acid fragment. However, the available evidence provides limited detail about its specific mechanism of action at the molecular and physiological level.

The research literature identifies TB-500 as a synthetic version of an active region of thymosin β₄, but the provided studies focus primarily on analytical detection methods for doping control rather than mechanistic studies. One study characterizes the synthesis and identification of the N-terminal acetylated 17-23 fragment that comprises TB-500, confirming its structural relationship to the parent thymosin beta-4 protein.

While thymosin beta-4 is known to play roles in cellular processes including wound healing, angiogenesis, and tissue regeneration, the specific mechanistic pathways through which the TB-500 fragment exerts its effects are not detailed in the available evidence. The compound has attracted attention for potential cardiovascular applications, as evidenced by an ongoing clinical trial examining its effects on cardiovascular biomarkers in patients with stable atherosclerotic cardiovascular disease.

Evidence Limitations: The current evidence base is limited regarding TB-500's precise mechanism of action. Most available research focuses on detection and analytical methods rather than mechanistic studies. More comprehensive research is needed to fully elucidate how TB-500 functions at the molecular and physiological levels.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.

TB-500 is a synthetic peptide based on an active fragment (amino acids 17-23) of thymosin β₄, a naturally occurring protein involved in cellular repair and regeneration processes. Current clinical evidence for TB-500 remains extremely limited.

Musculoskeletal and Athletic Applications

TB-500 is commonly promoted for musculoskeletal injuries and athletic performance enhancement, though rigorous clinical evidence supporting these uses is lacking. A 2026 systematic review on peptide therapies for musculoskeletal conditions and athletic performance included TB-500 among therapies examined for safety and efficacy, but specific findings for TB-500 were not detailed in the available evidence.

Cardiovascular Research

The only identified clinical trial investigating TB-500 is currently recruiting participants to evaluate its effects on cardiovascular biomarkers in patients with stable atherosclerotic cardiovascular disease (ASCVD). This Phase I/II study aims to assess TB-500's impact on cardiovascular markers, but results are not yet available.

Regulatory and Safety Considerations

TB-500 has been identified as a substance with "doping potential" and is monitored in anti-doping programs, particularly in equine sports. The development of analytical methods to detect TB-500 in biological samples reflects concerns about its use as a performance-enhancing substance rather than established therapeutic benefits.

Evidence Limitations

The clinical evidence base for TB-500 is notably sparse. While the compound is marketed and used for various conditions, particularly musculoskeletal injuries and recovery enhancement, peer-reviewed clinical trial data demonstrating safety and efficacy are extremely limited. Most available research focuses on detection methods rather than therapeutic outcomes.

Disclaimer: This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare professional before considering any peptide therapy, especially given the limited clinical evidence and regulatory status of TB-500.

Evidence Limitation: The safety profile of TB-500 is poorly characterized in human clinical research, with extremely limited published safety data available.

Known Side Effects

Current evidence provides minimal information about TB-500's side effect profile in humans. No comprehensive safety studies documenting adverse events, frequency, or severity have been identified in the available literature.

Contraindications

Specific contraindications for TB-500 have not been established through clinical research. The lack of safety data makes it impossible to define populations or conditions where TB-500 should be definitively avoided.

Drug Interactions

No drug interaction studies for TB-500 have been identified in the available evidence. Potential interactions with other medications remain unknown.

Populations That Should Avoid TB-500

Without adequate safety data, the following populations should exercise particular caution:

• Pregnant or breastfeeding women (no safety data available)
• Children and adolescents (no pediatric safety studies identified)
• Individuals with compromised immune systems
• Patients with active malignancies

Regulatory Status and Doping Concerns

TB-500 is not approved by major regulatory agencies (FDA, EMA) for therapeutic use. The compound has been flagged as a potential doping agent in athletic contexts, with specialized testing methods developed for detection in biological samples.

Current Clinical Investigation

One early-phase clinical trial (NCT07487363) is currently recruiting participants to evaluate TB-500 in cardiovascular applications, but safety results are not yet available.

Important Disclaimer: This information is for educational purposes only and does not constitute medical advice. The limited safety data available makes it impossible to provide comprehensive guidance on TB-500's risk profile. Consult with a qualified healthcare provider before considering any experimental therapy.

Research Papers and Clinical Trials

The current evidence base for TB-500 (Thymosin Beta-4) is quite limited, consisting primarily of analytical studies and one early-phase clinical trial.

Published Research

The available research focuses mainly on detection and characterization rather than therapeutic efficacy. A 2026 review in Sports Medicine examined the safety and efficacy of various peptide therapies for musculoskeletal injuries and athletic performance, including TB-500, though specific details about study design and sample sizes are not provided in the available evidence.

Two analytical chemistry studies from 2012 focused on TB-500's detection and synthesis. One study published in the Journal of Chromatography developed methods for detecting TB-500 in equine urine and plasma using liquid chromatography-mass spectrometry, reflecting concerns about its potential use as a performance-enhancing substance in sports. A companion study in Drug Testing and Analysis characterized the synthesis of TB-500's active fragment (amino acids 17-23 of thymosin beta-4).

Clinical Trials

Currently, there is one registered clinical trial (NCT07487363) investigating TB-500 for cardiovascular applications. This Phase 1/2 trial is examining TB-500's effects on cardiovascular biomarkers in patients with stable atherosclerotic cardiovascular disease (ASCVD). The trial is listed as recruiting, indicating it is in early stages, and specific enrollment numbers or preliminary results are not yet available.

Evidence Limitations

The research base for TB-500 remains quite thin. Most published work focuses on detection methods rather than clinical effectiveness, and the single clinical trial is still in progress. There is a notable absence of completed randomized controlled trials examining TB-500's therapeutic effects in humans.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare providers for treatment decisions.

Protocols

Important Disclaimer: The information below describes protocols reported in research literature and is not personalized medical advice. TB-500 is not approved by regulatory agencies for human therapeutic use. Any use should only occur under proper medical supervision and in accordance with applicable laws and regulations.

The available evidence on TB-500 (Thymosin Beta-4) dosing protocols is extremely limited. Most published research focuses on detection methods for anti-doping purposes rather than therapeutic protocols.

Research Context

TB-500 is described in the literature as a synthetic version of an active region of thymosin β₄, specifically the N-terminal acetylated 17-23 fragment. The compound has been identified primarily in the context of potential doping in athletic settings rather than established therapeutic applications.

Limited Protocol Information

The available literature does not provide comprehensive dosing protocols for TB-500. One ongoing clinical trial (NCT07487363) is investigating TB-500 for cardiovascular biomarkers in stable atherosclerotic cardiovascular disease, but specific dosing details from this Phase 1/2 trial are not yet published.

Evidence Limitations

The current evidence base has significant gaps:

• No established therapeutic dosing guidelines in peer-reviewed literature
• Limited human clinical data on safety and efficacy
• Most research focuses on analytical detection rather than clinical protocols
• The compound lacks regulatory approval for human therapeutic use

Safety Considerations

Given the limited safety and efficacy data, any consideration of TB-500 use should involve:

• Consultation with qualified healthcare providers
• Understanding of regulatory status and legal considerations
• Awareness that evidence for therapeutic benefits remains preliminary

The absence of well-documented protocols in the scientific literature reflects the early stage of research into this compound's potential therapeutic applications.

Outcomes

The available evidence on TB-500 (Thymosin Beta-4) outcomes is extremely limited, with most published research focusing on analytical detection methods rather than clinical efficacy.

Clinical Trial Evidence

One ongoing Phase 1/2 clinical trial (NCT07487363) is investigating TB-500's effects on cardiovascular biomarkers in patients with stable atherosclerotic cardiovascular disease (ASCVD). However, as this study is currently recruiting participants, no outcome data has been published.

Published Research Limitations

The peer-reviewed literature primarily consists of:

• Analytical chemistry studies developing methods to detect TB-500 in biological samples for anti-doping purposes
• Safety and regulatory reviews of peptide therapies that mention TB-500 but provide limited outcome data

Evidence Strength

The evidence for TB-500's clinical outcomes is currently insufficient. While one review article from 2026 addresses "Safety and Efficacy of Approved and Unapproved Peptide Therapies," the specific outcome measures, effect sizes, and clinical significance for TB-500 are not detailed in the available abstracts.

Knowledge Gaps

Measurable clinical outcomes such as:

• Specific biomarker changes
• Quantified symptom improvements
• Functional assessments
• Safety profiles

These remain largely unreported in the current peer-reviewed literature for TB-500.

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers before considering any therapeutic interventions.